ArticleRadiology advances2026
Pancreatic cancer diagnosis on unenhanced CT with deep learning for opportunistic diagnosis.
Article in Radiology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) is frequently missed on unenhanced CT examinations performed for unrelated clinical indications, where the pancreas is included incidentally and clinical suspicion is low. Purpose: To develop and validate a deep learning-based tool for PC diagnosis and risk stratification on unenhanced CT. Materials and Methods: This retrospective study included 3080 unenhanced CT studies of Taiwanese patients with PC, other pancreatic diseases and normal pancreas between 2004 and 2019 from a tertiary hospital, randomly divided into training, validation, and internal test sets. Unenhanced CT studies from United States institutions were used for external testing. A hybrid convolutional neural network-transformer model was trained for PC diagnosis and risk stratification. Performance was evaluated using sensitivity, specificity, and area under the curve (AUC), with comparisons to 2 radiologists by McNemar's test and exploratory decision curve analysis. Results: The internal dataset included 713 PCs (mean age, 64.6 ± 12.0 years; 384 men), 1661 normal pancreas and 706 other pancreatic diseases. In an exploratory comparison restricted to unenhanced CT (29 PCs, 31 controls), the sensitivity of computer-aided diagnosis (CAD) tool (89.7%, 72.6-97.8) seemed comparable with that of 1 radiologist (86.2%, 68.3-96.1) and higher than another (41.4%, 23.5-61.1); but wide confidence intervals and inter-radiologist variability warrant cautious interpretation. In the internal test set (142 PCs, 474 controls), sensitivity was 90.8% (84.9-95.0) and specificity 93.0% (90.4-95.2) (AUC: 0.98), with sensitivity comparable to radiologist reports based on enhanced and unenhanced CT (95.4%, 90.2-98.3; Conclusion: This tool may assist in the opportunistic detection and risk stratification of PC on unenhanced CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.